LY-674
98%
- Product Code: 202587
CAS:
425671-29-0
| Molecular Weight: | 409.48 g./mol | Molecular Formula: | C₂₃H₂₇N₃O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | 575.852 °C at 760 mmHg | |
| Density: | 1.21g/cm3 | Storage Condition: | 2-8°C |
Product Description:
LY-674 is primarily investigated for its potential in immunomodulatory therapies. It functions as a selective inhibitor of certain inflammatory pathways, making it a candidate for treating autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Research indicates it may suppress overactive immune responses by targeting specific signaling proteins involved in cytokine production, thereby reducing tissue inflammation and damage. It is also being explored in oncology for its ability to enhance anti-tumor immunity by modulating the tumor microenvironment. Due to its targeted mechanism, LY-674 shows promise in minimizing broad immunosuppressive effects, which could lead to fewer side effects compared to conventional therapies. Currently, it remains under preclinical and early clinical evaluation.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1mg | 10-20 days | ฿5,530.00 |
+
-
|
| 5mg | 10-20 days | ฿16,500.00 |
+
-
|
| 25mg | 10-20 days | ฿56,110.00 |
+
-
|
| 250mg | 10-20 days | ฿250,130.00 |
+
-
|
| 100mg | 10-20 days | ฿126,210.00 |
+
-
|
LY-674
LY-674 is primarily investigated for its potential in immunomodulatory therapies. It functions as a selective inhibitor of certain inflammatory pathways, making it a candidate for treating autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Research indicates it may suppress overactive immune responses by targeting specific signaling proteins involved in cytokine production, thereby reducing tissue inflammation and damage. It is also being explored in oncology for its ability to enhance anti-tumor immunity by modulating the tumor microenvironment. Due to its targeted mechanism, LY-674 shows promise in minimizing broad immunosuppressive effects, which could lead to fewer side effects compared to conventional therapies. Currently, it remains under preclinical and early clinical evaluation.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :